A novel [1,8]-naphthyridine derivative and its preparation method and application in organelle fluorescence imaging and organelle polarity detection
Through the D-π-A structure of the new [1,8]-naphthyridine derivative, the problem of the reduction of fluorescence emission in organelle targeting and high polarity environments is solved, and the organelle is realized Targeted fluorescent labeling and polarity detection, with low cytotoxicity and high light stability.
Patent Information
- Application Number
- CN202310088204.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-09
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-02-09
AI Technical Summary
Existing polar fluorescent probes lack targeting in cells, especially targeting organelles such as mitochondria, and their fluorescence emission is reduced in high polar environments, affecting the accuracy of organelles' polarity detection.
Develop a new [1,8]-naphthyridine derivative, which is connected to the nitrogen-containing heterocycle [1,8]-naphthyridine through carbon-carbon double bonds to form a neutral molecule with a D-π-A structure, with a smaller The cytotoxicity and different organelles targeting capabilities are used for organelles fluorescence imaging and polarity detection.
Targeted fluorescent labeling of mitochondria, lipid droplets, lysosomes and endoplasmic reticulum is achieved, which can detect polar changes in different organelles, has good photostability and low cytotoxicity, and provides higher cost-effectiveness. fluorescent probe selection.
Smart Images

Figure CN116283966B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of organic synthesis and fluorescent marker preparation, and in particular to a novel [1,8]-naphthyridine derivative and a preparation method thereof, and applications thereof in organelle fluorescence imaging and organelle polarity detection. Background Art
[0002] Abnormalities in the intracellular microenvironment (viscosity, polarity, pH, etc.) are associated with many physiological processes such as inflammation, neurodegenerative diseases, and cancer (see: Chem. Soc. Rev., 2021, 50, 8887-8902). Studies have shown that abnormal changes in the polarity of mitochondria can affect protein transport and interactions between biomacromolecules (see: Angew. Chem. Int. Ed., 2015, 54, 2510-2514). Abnormalities in cellular lipid droplets are associated with common metabolic diseases such as diabetes, fatty liver, and arteriosclerosis (see: Anal. Chem. 2021, 93, 8019-8026). Abnormal changes in the polarity of lysosomes can cause enzyme deficiency in lysosomes, leading to lysosomal storage diseases (see: Biomaterials, 2018, 164, 98-105). Misfolding and accumulation of proteins in the endoplasmic reticulum can lead to endoplasmic reticulum stress, a process also associated with diseases such as diabetes and Alzheimer's disease (see: Chem. Commun., 2014, 50, 11672-11675). Since polarity in cells is an important indicator of the physiological state of cells, polarity detection in cells is of great significance in diagnosing and tracking physiological processes.
[0003] Under low polarity conditions, common polar fluorescent probes have a fluorescence emission shift to a shorter wavelength and generally enhance fluorescence due to less charge separation in the probe molecular structure and weaker interaction with the solvent. In highly polar media, due to the dipole-dipole interaction between the probe and the solvent, the probe produces a greater charge separation and consumption of excited state energy, resulting in energy release through non-radiative decay of excited state intramolecular charge transfer (ICT). Therefore, polar probes will produce a red shift in fluorescence emission wavelength and a generally reduced fluorescence in a highly polar environment. However, polar probes currently still have some shortcomings, such as lack of organelle targeting. Polar probes with organelle targeting, such as polar probes targeting mitochondria, are salt compounds, but salt compounds in cells will cause changes in mitochondrial membrane potential, which will disrupt cell homeostasis. There are relatively few fluorescent probes for detecting cell polarity that have clear targeting and do not disrupt cell homeostasis. Summary of the invention
[0004] The technical problem to be solved by the present invention is to provide a novel [1,8]-naphthyridine derivative and its preparation method and application in organelle fluorescence imaging and organelle polarity detection. The [1,8]-naphthyridine derivative contains a nitrogen heterocyclic [1,8]-naphthyridine as the electron-withdrawing part of the molecular structure, which is connected to the electron-donating auxochromophore through a carbon-carbon double bond to form a typical D-π-A structured neutral molecule. This novel [1,8]-naphthyridine derivative has low cytotoxicity, and can have different organelle targeting capabilities by changing the type of auxochromophore, and can be applied to different organelle polarity detection.
[0005] In order to solve the above technical problems, the present invention provides the following technical solutions:
[0006] The first aspect of the present invention provides a [1,8]-naphthyridine derivative, wherein the [1,8]-naphthyridine derivative has the following general structural formula:
[0007]
[0008] Wherein, R is selected from one of the structural formulas shown in formula (I) to formula (IV):
[0009]
[0010] The second aspect of the present invention provides a method for preparing the [1,8]-naphthyridine derivative described in the first aspect, wherein [1,8]-naphthyridine and compound A are subjected to a reflux reaction in the presence of an organic solvent and an acidic catalyst to obtain the [1,8]-naphthyridine derivative.
[0011] Furthermore, when the compound A is 4-(N,N-diethyl)aminobenzaldehyde, R of the [1,8]-naphthyridine derivative is a structure represented by formula (I).
[0012] Furthermore, when the compound A is 4-diphenylamine benzaldehyde, R of the [1,8]-naphthyridine derivative is a structure represented by formula (II).
[0013] Furthermore, when the compound A is 4-piperazine-1-benzaldehyde, R of the [1,8]-naphthyridine derivative is a structure represented by formula (III).
[0014] Furthermore, when the compound A is 4-(ethyl(4-benzoyl)amino)-N-(2-((4-benzyl)sulfonamido)ethyl)butyramide, R of the [1,8]-naphthyridine derivative is a structure represented by formula (IV).
[0015] Furthermore, the molar ratio of the [1,8]-naphthyridine to compound A is preferably 1:1 to 1.5, more preferably 1:1.
[0016] Furthermore, the organic solvent is one or more of N,N-dimethylformamide, dimethyl sulfoxide, and N,N-dimethylacetamide.
[0017] Furthermore, the acidic catalyst is one or more of trimethylchlorosilane, dimethyldichlorosilane, and trimethylbromosilane, and is used for aldol condensation.
[0018] Furthermore, the temperature of the reflux reaction is 125-140° C., and the reaction time is 6-10 hours.
[0019] The third aspect of the present invention provides a use of the [1,8]-naphthyridine derivative described in the first aspect in the preparation of a fluorescent marker for organelle fluorescence imaging.
[0020] Furthermore, the cell organelle is a mitochondria, a lipid droplet, a lysosome or an endoplasmic reticulum.
[0021] Furthermore, when R of the [1,8]-naphthyridine derivative is a structure represented by formula (I), the [1,8]-naphthyridine derivative can be used as a green fluorescent marker for mitochondria.
[0022] Furthermore, when R of the [1,8]-naphthyridine derivative is a structure represented by formula (II), the [1,8]-naphthyridine derivative can be used as a green fluorescent marker for lipid droplets.
[0023] Furthermore, when R of the [1,8]-naphthyridine derivative is a structure represented by formula (III), the [1,8]-naphthyridine derivative can be used as a green fluorescent marker for lysosomes.
[0024] Furthermore, when R of the [1,8]-naphthyridine derivative is a structure represented by formula (IV), the [1,8]-naphthyridine derivative can be used as a green fluorescent marker of the endoplasmic reticulum.
[0025] Furthermore, the [1,8]-naphthyridine derivative is used as a fluorescent marker in organelle fluorescence imaging, and the specific operation is: co-culturing cells with a medium containing the [1,8]-naphthyridine derivative and a corresponding red commercial marker to perform cell imaging.
[0026] Furthermore, the concentration of the [1,8]-naphthyridine derivative in the culture medium is 3 to 10 μM.
[0027] The fourth aspect of the present invention provides a use of the [1,8]-naphthyridine derivative described in the first aspect in the preparation of a probe for detecting organelle polarity.
[0028] Furthermore, when R of the [1,8]-naphthyridine derivative is a structure represented by formula (I), the [1,8]-naphthyridine derivative can be used for detecting the polarity of mitochondria in cells.
[0029] Furthermore, when R of the [1,8]-naphthyridine derivative is a structure represented by formula (II), the [1,8]-naphthyridine derivative can be used for polarity detection of intracellular lipid droplets.
[0030] Furthermore, when R of the [1,8]-naphthyridine derivative is a structure represented by formula (III), the [1,8]-naphthyridine derivative can be used for polarity detection of intracellular lysosomes.
[0031] Furthermore, when R of the [1,8]-naphthyridine derivative is a structure represented by formula (IV), the [1,8]-naphthyridine derivative can be used for polarity detection of endoplasmic reticulum in cells.
[0032] Furthermore, the cells are co-cultured with the [1,8]-naphthyridine derivative according to claim 1 and a drug that induces changes in cell polarity in a culture medium, and cell imaging is performed, and changes in the fluorescence intensity of the fluorescent dye reflect changes in organelle polarity.
[0033] Furthermore, the fluorescence of the [1,8]-naphthyridine derivative in the corresponding organelle decreases with increasing polarity.
[0034] Furthermore, the drug inducing cell polarity change is nystatin, lipopolysaccharide, dimethyl sulfoxide or tunicamycin.
[0035] Furthermore, the concentration of the [1,8]-naphthyridine derivative in the culture medium is 5 to 10 μM.
[0036] Furthermore, the cells are placed in different culture media containing [1,8]-naphthyridine derivatives and different concentrations of drugs that induce cell polarity changes, and cell imaging is performed to test the changes in the fluorescence intensity of the fluorescent dye in the cells before and after the addition of the drug, thereby reflecting the changes in organelle polarity through the changes in fluorescence intensity.
[0037] Furthermore, the co-culture conditions are as follows: the cells are cultured in a saturated humidity, 37° C., 5% CO 2 incubator for 10 minutes, and then the [1,8]-naphthyridine derivative and the drug that induces cell polarity change are added and co-cultured for another 10 minutes.
[0038] Compared with the prior art, the present invention has the following beneficial effects:
[0039] 1. The present invention provides a series of novel [1,8]-naphthyridine derivatives, which connect the nitrogen-containing heterocyclic [1,8]-naphthyridine with the auxochromophore through a carbon-carbon double bond, thereby expanding the conjugation degree of [1,8]-naphthyridine to achieve a green channel, and can have the targeting ability of different organelles by changing the type of auxochromophore, and can be used as a green marker for mitochondria, lipid droplets, lysosomes and endoplasmic reticulum, and can also detect the polarity in organelles.
[0040] 2. The [1,8]-naphthyridine derivatives provided by the present invention have a simple synthesis method and the raw materials are cheap and readily available. Such [1,8]-naphthyridine derivatives have a typical D-π-A structure. The structure of the neutral molecule makes them relatively less cytotoxic, has good photostability, and has the ability to selectively target organelles, providing a lower-cost option for green fluorescent markers of different organelles. At the same time, they can detect polarity changes at the cellular level, which has great scientific significance and commercial value. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 It is a synthetic route for novel [1,8]-naphthyridine derivatives;
[0042] Figure 2 The UV-visible absorption spectra and fluorescence spectra of [1,8]-naphthyridine derivatives 1a-1d in 1,4-dioxane and methanol, respectively; wherein, (a) is the UV-visible absorption spectrum and fluorescence spectrum of 1a in 1,4-dioxane and methanol, (b) is the UV-visible absorption spectrum and fluorescence spectrum of 1b in 1,4-dioxane and methanol, (c) is the UV-visible absorption spectrum and fluorescence spectrum of 1c in 1,4-dioxane and methanol, and (d) is the UV-visible absorption spectrum and fluorescence spectrum of 1d in 1,4-dioxane and methanol;
[0043] Figure 3 is the residual absorption rate of [1,8]-naphthyridine derivatives 1a-1d after irradiation at different times;
[0044] Figure 4 is the cell survival rate after cells were cultured in medium containing different concentrations of [1,8]-naphthyridine derivatives 1a-1d;
[0045] Figure 5 Cell imaging images of [1,8]-naphthyridine derivatives 1a-1d in HeLa cells, respectively; wherein, (a1-a6) are cell imaging images of 1a in HeLa cells, (b1-b6) are cell imaging images of 1b in HeLa cells, (c1-c6) are cell imaging images of 1c in HeLa cells, and (d1-d6) are cell imaging images of 1d in HeLa cells;
[0046] Figure 6The cell imaging images of [1,8]-naphthyridine derivatives 1a-1d before and after the addition of drugs that induce cell polarity changes in HeLa cells; (A) is the cell imaging image of 1a before and after the addition of drugs in HeLa cells, (B) is the cell imaging image of 1c before and after the addition of drugs in HeLa cells, (C) is the cell imaging image of 1d before and after the addition of drugs in HeLa cells, and (D) is the cell imaging image of 1b before and after the addition of drugs in HeLa cells. DETAILED DESCRIPTION
[0047] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.
[0048] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0049] Example 1
[0050] This example relates to the preparation of a [1,8]-naphthyridine derivative 1a. The synthetic route is as follows: Figure 1 As shown, the specific preparation process is as follows:
[0051] [1,8]-naphthyridine (144.5 mg, 1 mmol) and 4-(N,N-diethyl)aminobenzaldehyde (177.6 mg, 1 mmol) were dissolved in 3 mL of N,N-dimethylformamide, and 700 microliters of trimethylsilyl chloride were added to the reaction mixture, and the reaction was refluxed at 130°C for 8 hours. TLC was used to monitor the progress of the reaction during the reaction. After the reaction was completed, about 20 mL of water was added to the reaction system, and the pH was adjusted to about 8 using a 10% NaOH aqueous solution. At this time, solids were generated, filtered, and the residue was collected. The crude product was purified by column chromatography, and the eluent was DCM / MeOH (60:1, v / v) to obtain about 97.9 mg of yellow solid compound 1a with a yield of 32%.
[0052] H NMR spectrum of [1,8]-naphthyridine derivative 1a 1H NMR (300MHz, CDCl3) δ (ppm) 9.06-9.05 (m, 1H, Ar-H), 8.11-8.05 (t, 2H, Ar-H), 7 .95(d,J=16.2Hz,1H,-N=CCH),7.63(d,J=8.4Hz,1H,Ar-H),7.55(d,J=8.4Hz,2 H,Ar-H),7.39-7.35(m,1H,Ar-H),7.24(d,J=15.9Hz,1H,-N=CC=CH),6.73(d,J =7.8Hz, 2H, Ar-H), 3.42 (q, J = 6.9Hz, 4H, 2×CH2), 1.20 (t, J = 7.1Hz, 6H, 2×CH3).
[0053] C NMR spectrum of [1,8]-naphthyridine derivative 1a 13 C NMR(151MHz,DMSO-d6)δ(ppm)160.00,156.27,153.89,148.64,137.91,137.41, 136.78,129.66,123.15,122.86,121.66,121.52,121.18,111.81,44.18,12.95.
[0054] HRMS (ESI) of [1,8]-naphthyridine derivative 1a + ): m / z calculated: C 20 H 22 N3 + ,[M+H] + : 304.1809, measured value: 304.1880.
[0055] Example 2
[0056] This example relates to the preparation of a [1,8]-naphthyridine derivative 1b. The synthetic route is as follows: Figure 1 As shown, the specific preparation process is as follows:
[0057] [1,8]-naphthyridine (147.6 mg, 1 mmol) and 4-diphenylamine benzaldehyde (273.5 mg, 1 mmol) were dissolved in 3 mL of N,N-dimethylformamide, and 700 microliters of trimethylsilyl chloride were added to the reaction mixture, and the reaction was refluxed at 130 ° C for 8 hours. TLC was used to monitor the progress of the reaction during the reaction. After the reaction was completed, about 20 mL of water was added to the reaction system, and the pH was adjusted to about 8 using a 10% NaOH aqueous solution. At this time, solids were generated, filtered, and the residue was collected. The crude product was purified by column chromatography, and the eluent was DCM / MeOH (40:1, v / v), and about 207.5 mg of orange solid compound 1b was obtained with a yield of 52%.
[0058] H NMR spectrum of [1,8]-naphthyridine derivative 1b 1 H NMR (300MHz, DMSO-d6) δ (ppm) 9.04-9.02 (m, 1H, Ar-H), 8.42-8.37 (m, 2H, Ar-H), 7.92 (d, J = 6.0Hz, 1H, Ar-H), 7.85 (d, J = 13.5Hz, 1H, -N = CCH ), 7.67 (d, J = 8.4Hz, 2H, Ar-H), 7.55 (dd, J = 8.1, 1H, 4.2Hz), 7.40-7.33 (m, 5H, Ar-H), 7.14-7.08 (m, 6H, Ar-H), 6.98 (d, J = 8.4Hz, 2H, Ar-H).
[0059] C NMR spectrum of [1,8]-naphthyridine derivative 1b 13 C NMR(151MHz,DMSO-d6)δ(ppm)159.32,156.09,154.15,148.51,147.09,138.31,137.5 5,135.59,130.15,130.05,129.20,126.70,125.19,124.25,122.36,122.00,121.37.
[0060] HRMS (ESI) of [1,8]-naphthyridine derivative 1b + ): m / z calculated: C 28 H 22 N3 + ,[M+H] + : 400.1809, measured value: 400.1813.
[0061] Example 3
[0062] This example relates to the preparation of a [1,8]-naphthyridine derivative 1c. The synthetic route is as follows: Figure 1 As shown, the specific preparation process is as follows:
[0063] Dissolve p-fluorobenzaldehyde (1.25 g, 10 mmol) in 30 mL of ethylene glycol methyl ether and place in a constant pressure dropping funnel. Piperazine (3.44 g, 40 mmol) was dissolved in 30 mL of water, stirred under reflux at 110 ° C, and the ethylene glycol methyl ether solution of p-fluorobenzaldehyde was slowly added dropwise with a constant pressure dropping funnel within 30 minutes, and the reaction time was about 5.5 h. After the reaction was completed, the reaction solution was extracted with DCM (3 × 20 mL), and the DCM phase was washed with saturated brine (30 mL), and the crude product was obtained by rotary evaporation. The crude product was purified by column chromatography, and the eluent was DCM / MeOH (60: 1, v / v), and about 1025.2 mg of light yellow solid 4-piperazine-1-benzaldehyde was obtained with a yield of 54%. (See: Anal.Chim.Acta., 2019, 1055, 133-139)
[0064] [1,8]-naphthyridine (151.0 mg, 1 mmol) and 4-piperazine-1-benzaldehyde (190.8 mg, 1 mmol) were dissolved in 3 mL of N,N-dimethylformamide, and 700 microliters of trimethylsilyl chloride were added to the reaction mixture. The reaction was refluxed at 130°C for 8 h. TLC was used to monitor the progress of the reaction. After the reaction was completed, about 20 mL of water was added to the reaction system, and the pH was adjusted to about 8 using a 10% aqueous solution of NaOH. The aqueous phase was then extracted with DCM (3×40 mL) and rotary evaporated to obtain a yellow solid, which was then washed with ethanol. The filtrate was recovered and the washing operation was repeated to obtain about 182.0 mg of yellow solid compound 1c with a yield of 57%.
[0065] H NMR spectrum of [1,8]-naphthyridine derivative 1c 1 H NMR(300MHz,DMSO-d6)δ(ppm)9.03-9.01(m,1H,Ar-H),8.39-8.36(m,2H,Ar-H),7.89-7.82(m,2H,Ar-H,-N=CCH),7.62(d,J=8.7Hz,2H,Ar-H),7 .53(dd,J=8.1,1H,4.2Hz),7.32(d,J=16.2Hz,1H,-N=CC=CH),6.99(d,J=8.7Hz,2H,Ar-H),3.17-3.14(m,4H,2×CH2),2.85-2.82(m,4H,2×CH2).
[0066] C NMR spectrum of [1,8]-naphthyridine derivative 1c 13C NMR(151MHz,DMSO-d6)δ(ppm)159.67,156.17,154.03,152.30,138.12,137.50, 136.26,129.14,126.42,124.76,121.83,121.78,121.30,115.17,48.59,45.67.
[0067] HRMS (ESI) of [1,8]-naphthyridine derivative 1c + ): m / z calculated: C 20 H 20 N4 + ,[M+Na] + : 339.1581, measured value: 339.1581.
[0068] Example 4
[0069] This example relates to the preparation of a [1,8]-naphthyridine derivative 1d. The synthetic route is as follows: Figure 1 As shown, the specific preparation process is as follows:
[0070] Synthesis reference of compounds 3a-3c: Bioorg. Med. Chem. Lett., 2011, 21, 3546-3549.
[0071] Compound 3c (1464.5 mg, 5.87 mmol) and LiOH (877.6 mg, 35.25 mmol) were dissolved in 15 mL of methanol and stirred at room temperature for 12 h. After the reaction was completed, the pH of the reaction mixture was adjusted to 5-6 using concentrated hydrochloric acid, and then the crude product was dissolved in 50 mL of water, and the aqueous phase was extracted with EA (3×30 mL), and the crude product was obtained by rotary evaporation. The crude product was purified by column chromatography with DCM / MeOH (80:1, v / v) as the eluent to obtain about 957.0 mg of light yellow solid 3d with a yield of 69%.
[0072] H NMR spectrum of compound 3d 1 H NMR (300MHz, CDCl3) δ (ppm) 9.71 (s, 1H, -CHO), 7.75 (d, J = 8.1Hz, 2H, Ar-H), 6.74-6.71 (m, 2H, Ar-H), 3. 50-3.41(m,4H,2×CH2),2.46(t,J=6.9Hz,2H,CH2),2.02-1.93(m,2H,CH2),1.22(t,J=7.2Hz,3H,CH3). 13C NMR (151MHz, CDCl3) δ (ppm) 190.35, 178.31, 152.39, 132.44, 124.81, 110.84, 49.46, 45.28, 30.96, 22.24, 12.22. HRMS(ESI + ): m / z calculated: C 13 H 17 NO3Na + ,[M+Na] + : 258.1101, measured value: 258.1101.
[0073] Compound 3d (476.6 mg, 2 mmol) and EDCl (627.5 mg, 3.2 mmol) were dissolved in 6 mL DCM and protected with nitrogen. After stirring at room temperature for about 30 minutes, a DCM solution of compound 3e (524.7 mg, 2.4 mmol) and 4-DMAP (62.3 mg, 0.5 mmol) was injected into the reaction system and continued to stir for 16 h. After the reaction was completed, the reaction solution was rotary evaporated to obtain a crude product. The crude product was purified by column chromatography, and the eluent was DCM / MeOH (30: 1, v / v) to obtain about 308.7 mg of a light yellow solid 2d with a yield of 36%.
[0074] H NMR spectrum of compound 2d 1 H NMR (300MHz, CDCl3) δ (ppm) 9.69 (s, 1H, -CHO), 7.74-7.68 (m, 4H, Ar-H), 7.31 (d, J=8.1Hz,2H,Ar-H),6.71(d,J=8.7Hz,2H,Ar-H),6.20(s,1H,-C(O)NH),5.30(s,1 H,-S(O)2NH),3.48-3.35(m,6H,3×CH2),3.09-3.04(m,2H,CH2),2.41(s,3H,-CH3 ), 2.25 (t, J = 6.9 Hz, 2H, CH2), 1.99-1.90 (m, 2H, CH2), 1.19 (t, J = 6.9 Hz, 3H, CH3). 13 CNMR(151MHz,CDCl3)δ(ppm)190.18,173.05,152.49,143.76,136.50,132.35,129.8 6,126.99,124.67,110.82,49.53,45.04,43.10,39.34,33.05,22.95,21.53,12.17. HRMS(ESI + ): m / z calculated: C 22 H 30N3O4 + ,[M+H] + : 432.1952, measured value: 432.1925.
[0075] [1,8]-naphthyridine (140.2 mg, 0.95 mmol) and compound 2d (408.2 mg, 0.95 mmol) were dissolved in 2.5 mL of N,N-dimethylformamide, and 680 microliters of trimethylsilyl chloride were added to the reaction mixture, and the reaction was refluxed at 130 ° C for 8 hours. TLC was used to monitor the progress of the reaction during the reaction. After the reaction was completed, about 20 mL of water was added to the reaction system, and the pH was adjusted to about 8 with a 10% NaOH aqueous solution. At this time, solids were generated, filtered, and the filter residue was collected. The crude product was purified by column chromatography, and the eluent was DCM / MeOH (80:1, v / v), and about 285.5 mg of red solid compound 1d was obtained with a yield of 57%.
[0076] H NMR spectrum of [1,8]-naphthyridine derivative 1d 1 H NMR (400MHz, DMSO-d6) δ (ppm) 9.01 (dd, J=4.4, 2.0Hz, 1H, Ar-H), 8.36-8.33 (m, 2H, Ar-H), 7.87-7.79 (m, 3H, Ar-H, -C(O)NH, -N=CCH), 7.6 8(d,J=8.0Hz,2H,Ar-H),7.60(t,J=6.0Hz,1H,-S(O)2NH),7.55(d,J=9.2Hz,2H,Ar-H),7.50(dd,J=8.0,4.4Hz,1H,Ar-H),7.40(d,J=8.0H z,2H,Ar-H),7.21(d,J=16Hz,1H,-N=CC=CH),6.74(d,J=8.8Hz,2H,Ar-H),3.41-3.36(m,2H,CH2),3.29-3.25(m,2H,CH2),3.11(q,J=6.4 Hz,2H,CH2),2.76(q,J=6.4Hz,2H,CH2),2.36(s,3H,CH3),2.11(t,J=7.2Hz,2H,CH2),1.77-1.70(m,2H,CH2),1.10(t,J=7.0Hz,3H,CH3).
[0077] [1,8]-Naphthyridine derivatives 1d 13C NMR(151MHz,DMSO-d6)δ(ppm)172.40,159.99,156.25,153.91,148.82,143.10,137.93,137.82,137.43,136.77,130.09,1 29.61,126.95,123.20,122.86,121.66,121.55,121.21,111.84,48.45,44.64,42.53,38.90,32.70,23.33,21.38,12.66.
[0078] HRMS (ESI) of [1,8]-naphthyridine derivative 1d + ): m / z calculated: C 22 H 30 N3O4 + ,[M+H] + : 558.2534, measured value: 558.2591.
[0079] Performance testing and application
[0080] (1) Fluorescence performance test
[0081] The ultraviolet absorption and fluorescence emission spectra of the [1,8]-naphthyridine derivatives prepared in Examples 1 to 4 (all at a concentration of 10 μM) were tested in 1,4-dioxane and methanol, with the abscissa being the wavelength and the ordinate being the absorbance or fluorescence intensity, respectively. The test results are shown in FIG. Figure 2 As shown:
[0082] Figure 2 (a) in the figure are the ultraviolet absorption and fluorescence emission spectra of [1,8]-naphthyridine derivative 1a in 1,4-dioxane and methanol, respectively. It can be seen from the figure that [1,8]-naphthyridine derivative 1a has maximum absorption at 419nm; in the fluorescence emission spectrum in 1,4-dioxane, [1,8]-naphthyridine derivative 1a has the highest fluorescence intensity at 516nm, at which time the excitation wavelength is 429nm and the slit width is 1.5 / 3nm.
[0083] Figure 2 (b) in the figure are the ultraviolet absorption and fluorescence emission spectra of [1,8]-naphthyridine derivative 1b in 1,4-dioxane and methanol, respectively. It can be seen from the figure that [1,8]-naphthyridine derivative 1b has maximum absorption at 408nm; in the fluorescence emission spectrum in 1,4-dioxane, [1,8]-naphthyridine derivative 1b has the highest fluorescence intensity at 503nm, at which time the excitation wavelength is 414nm and the slit width is 1.5 / 3nm.
[0084] Figure 2(c) in the figure are the ultraviolet absorption and fluorescence emission spectra of [1,8]-naphthyridine derivative 1c in 1,4-dioxane and methanol, respectively. It can be seen from the figure that [1,8]-naphthyridine derivative 1c has maximum absorption at 385nm; in the fluorescence emission spectrum in 1,4-dioxane, [1,8]-naphthyridine derivative 1c has the highest fluorescence intensity at 503nm, at which time the excitation wavelength is 383nm and the slit width is 3 / 3nm.
[0085] Figure 2 (d) in the figure are the ultraviolet absorption and fluorescence emission spectra of [1,8]-naphthyridine derivative 1d in 1,4-dioxane and methanol, respectively. It can be seen from the figure that [1,8]-naphthyridine derivative 1d has the maximum absorption at 415nm; in the fluorescence emission spectrum in 1,4-dioxane, [1,8]-naphthyridine derivative 1d has the highest fluorescence intensity at 520nm, at which time the excitation wavelength is 416nm and the slit width is 3 / 3nm.
[0086] (2) Photostability test
[0087] The [1,8]-naphthyridine derivatives 1a-1d prepared in Examples 1 to 4 were subjected to a photostability test. The specific operation was as follows: Weigh the corresponding mass of [1,8]-naphthyridine derivatives 1a-1d, dissolve each [1,8]-naphthyridine derivative in acetonitrile to prepare a solution with a dye concentration of 10 μM, and irradiate all samples with a Philips iodine tungsten lamp (500W), with the distance between the lamp and the sample set to 25 cm. Place an 8 cm thick NaNO2 (60 g / L) cold trap between the lamp and the sample to eliminate heat and short-wavelength light. Irradiate continuously for 6 hours, with an ultraviolet fluorescence test performed every half an hour. After six hours, the photostability is calculated by comparing the absorption intensity after irradiation at different times with the initial absorption intensity to calculate the residual absorption rate.
[0088] The test results are as follows Figure 3 As shown, the residual absorption rates of [1,8]-naphthyridine derivatives 1a-1d decreased with the increase of irradiation time. However, after continuous irradiation for 6 hours, the residual absorption rates of [1,8]-naphthyridine derivatives 1a-1d were 1a: 57%, 1b: 79%, 1c: 85%, and 1d: 63%, respectively. It can be seen that this type of [1,8]-naphthyridine derivatives 1a-1d have relatively good photostability.
[0089] (3) Cytotoxicity test
[0090] The [1,8]-naphthyridine derivatives 1a-1d prepared in Examples 1 to 4 were subjected to cytotoxicity tests, and the viability of HeLa cells in the presence of different concentrations and types of [1,8]-naphthyridine derivatives was measured using the CCK-8 method. The specific operation was as follows: HeLa cells were incubated with different concentrations (0, 2, 4, 6, 8 and 10 μM) and different types ([1,8]-naphthyridine derivatives 1a, 1b, 1c, 1d) of [1,8]-naphthyridine derivatives for 6 hours.
[0091] The cytotoxicity test results of [1,8]-naphthyridine derivatives 1a-1d are as follows Figure 4 As shown, the vertical axis represents the cell viability of HeLa cells cultured with [1,8]-naphthyridine derivatives as 1a-1d, and the cell viability decreases with the increase of the concentration of [1,8]-naphthyridine derivatives. After incubation in a culture medium with a [1,8]-naphthyridine derivative concentration of 10 μM for 6 hours, the cell viability is 1a: 85%, 1b: 68%, 1c: 78%, 1d: 85%, respectively. This result shows that the [1,8]-naphthyridine derivatives prepared by the present invention have low cytotoxicity and are suitable for living cell imaging.
[0092] Cell survival rate (%) = (A sample –A b ) / (A c –A b ), where A c : Negative control (including culture medium and cells, without the addition of the [1,8]-naphthyridine derivative to be tested), A b : Blank (including the [1,8]-naphthyridine derivative to be tested and culture medium, without cell addition), A sample : Test group (including culture medium, cells and [1,8]-naphthyridine derivatives to be tested).
[0093] (4) Fluorescence imaging of organelles
[0094] a. Targeted imaging of mitochondria
[0095] [1,8]-naphthyridine derivative 1a was prepared into a mother solution using DMSO (dimethyl sulfoxide), and then added to a regular cell culture medium to make the concentration of [1,8]-naphthyridine derivative 1a in the cell culture medium 3μM, and then co-cultured with HeLa cells in a saturated humidity, 37°C, 5% CO2 incubator (the same experiment below) for 10 minutes, and then the commercial mitochondrial red marker Mito Tracker Red CMXRos (3μM) was added and cultured for another 10 minutes; then washed three times with PBS buffer, and the cells were imaged using a laser confocal microscope. The green light channel was excited at a wavelength of 488nm, and the fluorescence signal in the range of 500-580nm was collected. The red light channel was excited at a wavelength of 561nm, and the fluorescence signal in the range of 600-750nm was collected.
[0096] like Figure 5 As shown in (a1) to (a5), (a1) is a bright field image, (a2) is a cell image of [1,8]-naphthyridine derivative 1a, (a3) is a cell image of a commercial mitochondrial red marker, (a4) is an overlay of the green and red channels, (a5) is a colocalization experiment, and the colocalization coefficient reaches 0.90. (a6) is the fluorescence intensity of the ROI line in the overlay image. The fluorescence intensity of mitochondria labeled with [1,8]-naphthyridine derivative 1a is similar to that of the commercial mitochondrial red marker. The above cell imaging results show that [1,8]-naphthyridine derivative 1a can well label mitochondria in HeLa cells and can be used as a mitochondrial green marker.
[0097] b. Targeted imaging of lipid droplets
[0098] The concentration of [1,8]-naphthyridine derivative 1b in the cell culture medium was 5 μM, and then co-cultured with HeLa cells in a saturated humidity, 37°C, 5% CO2 incubator (the same experiment below) for 10 minutes, followed by the addition of commercial lipid droplet red marker Nile Red (50 nM) for another 10 minutes; then washed three times with PBS buffer, and the cells were imaged using a laser confocal microscope. The green light channel was excited at a wavelength of 488 nm, and the fluorescence signal in the range of 500-580 nm was collected. The red light channel was excited at a wavelength of 561 nm, and the fluorescence signal in the range of 600-750 nm was collected.
[0099] like Figure 5As shown in (b1) to (b5), (b1) is a bright field image, (b2) is a cell image of [1,8]-naphthyridine derivative 1b, (b3) is a cell image of a commercial lipid droplet red marker, (b4) is an overlay of the green and red channels, (b5) is a colocalization experiment, with a colocalization coefficient of 0.86, and (b6) is the fluorescence intensity of the ROI line in the overlay. The fluorescence intensity of lipid droplets marked by [1,8]-naphthyridine derivative 1b is higher than that of the commercial lipid droplet red marker. Cell imaging shows that [1,8]-naphthyridine derivative 1b can well mark lipid droplets in HeLa cells and can be used as a lipid droplet green marker.
[0100] c. Targeted imaging of lysosomes
[0101] The concentration of [1,8]-naphthyridine derivative 1c in the cell culture medium was 10 μM, and then co-cultured with HeLa cells in a saturated humidity, 37°C, 5% CO2 incubator (the same experiment below) for 10 minutes, followed by the addition of commercial lysosomal red marker Lyso Tracker Red (1 μM) for another 10 minutes; then washed three times with PBS buffer, and the cells were imaged using a laser confocal microscope. The green light channel was excited at a wavelength of 488 nm, and fluorescence signals in the range of 500-580 nm were collected. The red light channel was excited at a wavelength of 561 nm, and fluorescence signals in the range of 600-750 nm were collected.
[0102] like Figure 5 As shown in (c1) to (c5), (c1) is a bright field image, (c2) is a cell image of [1,8]-naphthyridine derivative 1c, (c3) is a cell image of a commercial lysosome red marker, (c4) is an overlay of the green and red channels, (c5) is a colocalization experiment, with a colocalization coefficient of up to 0.96, and (c6) is the fluorescence intensity of the ROI line in the overlay. The fluorescence intensity of lysosomes marked by [1,8]-naphthyridine derivative 1c is higher than that of the commercial lysosome red marker. Cell imaging shows that [1,8]-naphthyridine derivative 1c can well mark lysosomes in HeLa cells and can be used as a lysosome green marker.
[0103] d. Targeted imaging of the endoplasmic reticulum
[0104] The concentration of [1,8]-naphthyridine derivative 1d in the cell culture medium was 10 μM, and then co-cultured with HeLa cells in a saturated humidity, 37°C, 5% CO2 incubator (the same experiment below) for 10 minutes, followed by the addition of commercial endoplasmic reticulum red marker ERTracker Red (1 μM) for another 10 minutes; then washed three times with PBS buffer, and the cells were imaged using a laser confocal microscope. The green light channel was excited at a wavelength of 488 nm, and the fluorescence signal in the range of 500-580 nm was collected. The red light channel was excited at a wavelength of 561 nm, and the fluorescence signal in the range of 600-750 nm was collected.
[0105] like Figure 5 As shown in (d1) to (d5), (d1) is a bright field image, (d2) is a cell image of dye 1d, (d3) is a cell image of a commercial endoplasmic reticulum red marker, (d4) is an overlay of the green and red channels, (d5) is a colocalization experiment, the colocalization coefficient is 0.91, and (d6) is the fluorescence intensity of the ROI line in the overlay image, which is consistent. Cell imaging shows that [1,8]-naphthyridine derivative 1d can well label the endoplasmic reticulum in HeLa cells and can be used as an endoplasmic reticulum green marker.
[0106] (5) Organelle polarity detection
[0107] a. Detection of mitochondrial polarity
[0108] The concentration of [1,8]-naphthyridine derivative 1a in the culture medium was 10 μM, and the concentration of nystatin was 10 μM. The cells were co-cultured for 30 minutes, washed three times with PBS buffer, and then imaged using a laser confocal microscope. The green light channel was excited at a wavelength of 488 nm, and fluorescence signals in the range of 500-580 nm were collected.
[0109] like Figure 6 As shown in (A), (a) is a cell image of [1,8]-naphthyridine derivative 1a, (a1) is a bright field image, (a2) is an overlay of (a) and (a1), (b) is a cell image of [1,8]-naphthyridine derivative 1a with nystatin, (b1) is a bright field image, (b2) is an overlay of (b) and (b1), and (c) is the average fluorescence intensity. The cell imaging results show that after the addition of nystatin to increase mitochondrial polarity, the fluorescence intensity of [1,8]-naphthyridine derivative 1a is significantly reduced.
[0110] b. Detection of lipid droplet polarity
[0111] The concentration of [1,8]-naphthyridine derivative 1b in the culture medium was 5 μM, and the concentration of lipopolysaccharide was 50 μg / mL. The cells were co-cultured for 30 minutes, washed three times with PBS buffer, and then imaged using a laser confocal microscope. The green light channel was excited at a wavelength of 488 nm, and fluorescence signals in the range of 500-580 nm were collected.
[0112] like Figure 6 As shown in (D), (a) is the cell imaging of [1,8]-naphthyridine derivative 1b, (a1-a4) are the cell imaging of [1,8]-naphthyridine derivative 1b within 3 hours after the addition of lipopolysaccharide, (b-b4) are bright field imaging, and (c) is the average fluorescence intensity. The cell imaging results show that after the polarity of lipid droplets is reduced by the addition of lipopolysaccharide, the fluorescence intensity of [1,8]-naphthyridine derivative 1b increases significantly, and the fluorescence intensity increases with the extension of the time of adding lipopolysaccharide.
[0113] c. Detection of lysosomal polarity
[0114] The concentration of [1,8]-naphthyridine derivative 1c in the culture medium was 10 μM, and the amount of dimethyl sulfoxide was 10 μL. The cells were co-cultured for 30 minutes, washed three times with PBS buffer, and then imaged using a laser confocal microscope. The green light channel was excited at 488 nm, and the fluorescence signal in the range of 500-580 nm was collected.
[0115] like Figure 6 As shown in (B), (a) is a cell image of [1,8]-naphthyridine derivative 1c, (a1) is a bright field image, (a2) is an overlay of (a) and (a1), (b) is a cell image of [1,8]-naphthyridine derivative 1c with dimethyl sulfoxide, (b1) is a bright field image, (b2) is an overlay of (b) and (b1), and (c) is the average fluorescence intensity. The cell imaging results show that after the lysosomal polarity is reduced by adding dimethyl sulfoxide, the fluorescence intensity of [1,8]-naphthyridine derivative 1c increases significantly.
[0116] d. Detection of endoplasmic reticulum polarity
[0117] The concentration of [1,8]-naphthyridine derivative 1d in the culture medium was 10 μM, and the concentration of tunicamycin was 500 μg / mL. The cells were co-cultured for 30 minutes, washed three times with PBS buffer, and then imaged using a laser confocal microscope. The green light channel was excited at a wavelength of 488 nm, and fluorescence signals in the range of 500-580 nm were collected.
[0118] like Figure 6As shown in (C), (a) is a cell image of [1,8]-naphthyridine derivative 1d, (a1) is a bright field image, (a2) is an overlay of (a) and (a1), (b) is a cell image of [1,8]-naphthyridine derivative 1d with tunicamycin, (b1) is a bright field image, (b2) is an overlay of (b) and (b1), and (c) is the average fluorescence intensity. The cell imaging results show that after the endoplasmic reticulum polarity is increased by adding tunicamycin, the fluorescence intensity of [1,8]-naphthyridine derivative 1d is significantly reduced.
[0119] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.
Claims
1. A [1,8]-naphthyridine derivative, characterized in that The [1,8]-naphthyridine derivative has the following general structural formula: , Wherein, R is selected from one of the structural formulas shown in formula (I) to formula (IV): 。 2. A method for preparing the [1,8]-naphthyridine derivative according to claim 1, characterized in that: The compound represented by formula (V) and the compound represented by formula (VI) are subjected to a reflux reaction in the presence of an organic solvent and a catalyst to obtain the [1,8]-naphthyridine derivative; the catalyst is one or more of trimethylsilyl chloride, dimethyldichlorosilane, and trimethylsilyl bromide; The structure of the compound represented by formula (V) is as follows: ; The structure of the compound represented by formula (VI) is as follows: ; Wherein, R is selected from one of the structural formulas shown in formula (I) to formula (IV): 。 3. The preparation method according to claim 2, characterized in that: The molar ratio of the compound represented by formula (V) to the compound represented by formula (VI) is 1:1-1.
5.
4. The preparation method according to claim 2, characterized in that: The organic solvent is one or more of N,N-dimethylformamide, dimethyl sulfoxide, and N,N-dimethylacetamide.
5. The preparation method according to claim 2, characterized in that: The temperature of the reflux reaction is 125-140°C, and the reaction time is 6-10 h.
6. Use of a [1,8]-naphthyridine derivative wherein R in claim 1 is a structure represented by formula (I) in the preparation of a fluorescent marker for mitochondrial fluorescence imaging.
7. Use of a [1,8]-naphthyridine derivative wherein R in claim 1 is a structure represented by formula (II) in the preparation of a fluorescent marker for lipid droplet fluorescence imaging.
8. Use of a [1,8]-naphthyridine derivative wherein R in claim 1 is a structure represented by formula (III) in the preparation of a fluorescent marker for lysosomal fluorescence imaging.
9. Use of a [1,8]-naphthyridine derivative wherein R in claim 1 is a structure represented by formula (IV) in the preparation of a fluorescent marker for endoplasmic reticulum fluorescence imaging.
10. Use of a [1,8]-naphthyridine derivative wherein R in claim 1 is a structure represented by formula (I) in the preparation of a probe for detecting mitochondrial polarity.
11. Use of a [1,8]-naphthyridine derivative wherein R in claim 1 is a structure represented by formula (II) in the preparation of a probe for lipid droplet polarity detection.
12. Use of a [1,8]-naphthyridine derivative wherein R in claim 1 is a structure represented by formula (III) in the preparation of a probe for detecting lysosomal polarity.
13. Use of a [1,8]-naphthyridine derivative wherein R in claim 1 is a structure represented by formula (IV) in the preparation of a probe for endoplasmic reticulum polarity detection.
14. The use according to any one of claims 10 to 13, characterized in that: The cells are co-cultured with the [1,8]-naphthyridine derivative and a drug that induces changes in cell polarity in a culture medium, and cell imaging is performed. Changes in the fluorescence intensity of the fluorescent dye reflect changes in the polarity of the organelles.
15. The use according to claim 14, wherein the drug that induces cell polarity change is nystatin, lipopolysaccharide, dimethyl sulfoxide or tunicamycin.
